RATIONALE: Extracellular signal-regulated protein kinase (ERK(1/2)) is a member of the mitogen-activated protein kinase (MAPK) signaling pathway and a key molecular target for ethanol (EtOH) and other drugs of abuse. OBJECTIVE: The aim of the study was to assess the role of two MAPK pathways, ERK(1/2) and c-Jun N-terminal kinase (JNK), on the modulation of EtOH and sucrose self-administration. MATERIALS AND METHODS: C57BL/6J mice were trained to lever press on a fixed-ratio 4 schedule with 9% EtOH/2% sucrose, or 2% sucrose, as the reinforcer. In experiments 1 and 2, mice were injected with the MEK(1/2) inhibitor SL 327 (0-100 mg/kg) and the JNK inhibitor AS 6012452 (0-56 mg/kg) prior to self-administration. In experiment 3, SL 327 (0-100 mg/kg) was administered prior to performance on a progressive ratio (PR) schedule of EtOH reinforcement. In experiment 4, SL 327 and AS 601245 were injected 2 h before a locomotor test. RESULTS: SL 327 (30 mg/kg) significantly increased EtOH self-administration without affecting locomotion. Higher doses of SL 327 and AS 601245 reduced EtOH-reinforced responding and locomotor activity. Reductions of both ligands on sucrose self-administration were due to decreases in motor activity. SL 327 pretreatment had no effect on PR responding. CONCLUSIONS: ERK(1/2) activity is more directly involved in modulating the reinforcing properties of EtOH than JNK activity due to its selective potentiation of EtOH-reinforced responding. The specificity of this effect to EtOH self-administration, rather than sucrose self-administration, suggests that the mechanism by which ERK(1/2) increases EtOH-reinforced responding does not generalize to all reinforcing solutions and is not due to increased motivation to consume EtOH.
RATIONALE: Extracellular signal-regulated protein kinase (ERK(1/2)) is a member of the mitogen-activated protein kinase (MAPK) signaling pathway and a key molecular target for ethanol (EtOH) and other drugs of abuse. OBJECTIVE: The aim of the study was to assess the role of two MAPK pathways, ERK(1/2) and c-Jun N-terminal kinase (JNK), on the modulation of EtOH and sucrose self-administration. MATERIALS AND METHODS: C57BL/6J mice were trained to lever press on a fixed-ratio 4 schedule with 9% EtOH/2% sucrose, or 2% sucrose, as the reinforcer. In experiments 1 and 2, mice were injected with the MEK(1/2) inhibitor SL 327 (0-100 mg/kg) and the JNK inhibitor AS 6012452 (0-56 mg/kg) prior to self-administration. In experiment 3, SL 327 (0-100 mg/kg) was administered prior to performance on a progressive ratio (PR) schedule of EtOH reinforcement. In experiment 4, SL 327 and AS 601245 were injected 2 h before a locomotor test. RESULTS: SL 327 (30 mg/kg) significantly increased EtOH self-administration without affecting locomotion. Higher doses of SL 327 and AS 601245 reduced EtOH-reinforced responding and locomotor activity. Reductions of both ligands on sucrose self-administration were due to decreases in motor activity. SL 327 pretreatment had no effect on PR responding. CONCLUSIONS:ERK(1/2) activity is more directly involved in modulating the reinforcing properties of EtOH than JNK activity due to its selective potentiation of EtOH-reinforced responding. The specificity of this effect to EtOH self-administration, rather than sucrose self-administration, suggests that the mechanism by which ERK(1/2) increases EtOH-reinforced responding does not generalize to all reinforcing solutions and is not due to increased motivation to consume EtOH.
Authors: Clyde W Hodge; Michael F Miles; Amanda C Sharko; Rebekah A Stevenson; Jennie R Hillmann; Veronique Lepoutre; Joyce Besheer; Jason P Schroeder Journal: Psychopharmacology (Berl) Date: 2005-11-15 Impact factor: 4.530
Authors: Susan M Ferguson; Stefania Fasano; Pengwei Yang; Riccardo Brambilla; Terry E Robinson Journal: Neuropsychopharmacology Date: 2006-01-11 Impact factor: 7.853
Authors: Larry D Reid; Peter W Marinelli; Shannon M Bennett; Lauren T Fiscale; Sandy P Narciso; Charlotte J Oparowski; Meta L Reid; Brooke A Merrigan; John Moricone; Christopher L Hubbell; Christina Gianoulakis Journal: Pharmacol Biochem Behav Date: 2002-06 Impact factor: 3.533
Authors: Abigail E Agoglia; Amanda C Sharko; Kelly E Psilos; Sarah E Holstein; Grant T Reid; Clyde W Hodge Journal: Alcohol Clin Exp Res Date: 2015-02-19 Impact factor: 3.455
Authors: Pamela Metten; Ovidiu D Iancu; Stephanie E Spence; Nicole A R Walter; Denesa Oberbeck; Christina A Harrington; Alexandre Colville; Shannon McWeeney; Tamara J Phillips; Kari J Buck; John C Crabbe; John K Belknap; Robert J Hitzemann Journal: Alcohol Clin Exp Res Date: 2014-12 Impact factor: 3.455
Authors: Rianne R Campbell; Racquel D Domingo; Amy R Williams; Melissa G Wroten; Hadley A McGregor; Ryan S Waltermire; Daniel I Greentree; Scott P Goulding; Andrew B Thompson; Kaziya M Lee; Sema G Quadir; C Leonardo Jimenez Chavez; Michal A Coelho; Adam T Gould; Georg von Jonquieres; Matthias Klugmann; Paul F Worley; Tod E Kippin; Karen K Szumlinski Journal: J Neurosci Date: 2019-02-08 Impact factor: 6.167
Authors: R Renteria; Z M Jeanes; R A Mangieri; E Y Maier; D M Kircher; T R Buske; R A Morrisett Journal: Int Rev Neurobiol Date: 2016-03-24 Impact factor: 3.230
Authors: Joyce Besheer; Kristen R Fisher; Reginald Cannady; Julie J M Grondin; Clyde W Hodge Journal: Behav Brain Res Date: 2011-12-23 Impact factor: 3.332